Nucleic acid formulations for gene delivery and methods of use
View Patent ↗A nucleic acid formulation for use in gene delivery comprising a nucleic acid and an anionic polymer is disclosed. Examples of the anionic polymer includes anionic amino acid polymer or poly-amino acid (such as poly-L-glutamic acid, poly-D-glutamic acid, poly-L-aspartic acid, poly-D-aspartic acid), poly-acrylic acid, polynucleotides, poly galacturonic acid, and poly vinyl sulfate.
1. A method of delivering a nucleic acid encoding a therapeutic gene product to a cell comprising:
introducing the nucleic acid encoding the therapeutic gene product to a cell in a formulation comprising the nucleic acid formulated with an anionic polymer selected from the group consisting of: poly glutamic acid, poly aspartic acid, poly galacturonic acid, poly vinyl sulfate, and co-polymers of glutamic and aspartic acid, and salts thereof,
wherein the anionic polymer is non-encapsulating and the formulation does not include a cationic polymer.
2. The method of claim 1 , wherein the anionic polymer is selected from the group consisting of poly glutamic acid and poly aspartic acid, and salts thereof.
3. The method of claim 1 , wherein the anionic polymer is characterized by a molecular weight in the range from 2,000 to 100,000 Daltons.
4. The method of claim 3 , wherein the anionic polymer is characterized by a molecular weight in the range from about 15,000 to about 50,000 Daltons.
5. The method of claim 3 , wherein the anionic polymer is characterized by a molecular weight in the range from about 2,000 to about 15,000 Daltons.
6. The method of claim 3 , wherein the anionic polymer is characterized by a molecular weight in the range from about 50,000 to about 100,000 Daltons.
7. The method of claim 1 , wherein the anionic polymer or salt thereof is formulated with the nucleic acid encoding the therapeutic gene product at a polymer concentration ranging from 1 to 12 mg/ml.
8. The method of claim 7 , wherein the anionic polymer or salt thereof is formulated with the nucleic acid encoding the therapeutic gene product at a polymer concentration of about 2 to about 6 mg/ml.
9. The method of claim 1 , wherein the formulation is isotonic.
10. The method of claim 1 , wherein the formulated nucleic acid is introduced to the cell in a tissue in vivo.
11. The method of claim 10 , wherein the tissue is a muscle tissue.
12. The method of claim 1 , further comprising a step of storing the formulated nucleic acid by liquid storage, lyophilization and/or freezing.
13. The method of claim 1 , wherein the therapeutic gene product is selected from the group consisting of: mRNA templates for translation, ribozymes, antisense RNA, proteins, glycoproteins, lipoproteins, phosphoproteins and polypeptides.
14. The method of claim 13 , wherein the therapeutic gene product is a protein selected from the group consisting of growth hormones, growth factors, cytokines, clotting factors, antigens, and antigenic factors.
15. The method of claim 14 , wherein the clotting factor is a Factor IX.
16. The method of claim 14 , wherein the growth factor is an erythropoietin.
17. The method of claim 14 , wherein the cytokine is an interferon.
18. The method of claim 1 , wherein the poly glutamic acid is a salt of poly-L-glutamic acid and is present in the formulation at a concentration of 1 to 12 mg/ml.
19. The method of claim 18 , wherein the salt of poly-L-glutamic acid is a sodium salt and is present in the formulation at a concentration of about 6 mg/ml.
20. The method of claim 10 , wherein the formulated nucleic acid is introduced into the tissue in vivo by injection.
21. The method of claim 10 , further comprising a step of electroporating the tissue.
22. The method of claim 21 , wherein the electroporating is performed through the use of a device configured and arranged to cause pulse voltage delivery of the formulated nucleic acid.
23. The method of claim 22 , wherein the pulse voltage delivery is performed at a pulse strength in a range of about 200V/cm to about 1,800 V/cm.
24. The method of claim 23 , wherein the pulse voltage delivery is performed at a pulse strength selected from the group consisting of about: 200V/cm, 375V/cm, and 1,800 V/cm.
25. The method of claim 22 , wherein the pulse voltage delivery is performed at a pulse length in the range of about 100 microsec to about 25 millisec.
26. The method of claim 25 , wherein the pulse voltage delivery is performed at a pulse length selected from the group consisting of about: 100 microsec 25 millisec, and 60 millisec.
27. The method of claim 22 , wherein the pulse voltage delivery is performed using a plurality of pulses.
28. The method of claim 27 , wherein the plurality of pulses ranges from 2 to about 6 pulses.
29. The method of claim 22 , wherein the pulse voltage delivery is performed using a square wave pulse.
30. The method of claim 22 , wherein the method induces an immune response.
31. A method for delivering a therapeutic gene product to a mammalian tissue, comprising the steps of:
providing a non-condensing, non-encapsulating formulation comprising a nucleic acid encoding the therapeutic gene product and an anionic polymer selected from the group consisting of: poly glutamic acid, poly aspartic acid, poly galacturonic acid, poly vinyl sulfate, and co-polymers of glutamic and aspartic acid, and salts thereof,
introducing the formulation to the mammalian tissue in vivo; and
electroporating the tissue, whereby the nucleic acid is introduced into cells in the tissue and the therapeutic gene product is expressed.
32. The method of claim 31 , wherein the electroporating is performed through the use of a device configured and arranged to cause pulse voltage delivery of the formulated nucleic acid.
33. The method of claim 32 , wherein the pulse voltage delivery is performed at a pulse strength in a range of about 200V/cm to about 1,800 V/cm.
34. The method of claim 33 , wherein the pulse voltage delivery is performed at a pulse strength selected from the group consisting of about: 200V/cm, 375V/cm, and 1,800 V/cm.
35. The method of claim 32 , wherein the pulse voltage delivery is performed at a pulse length in the range of about 100 microsec to about 25 millisec.
36. The method of claim 35 , wherein the pulse voltage delivery is performed at a pulse length selected from the group consisting of about: 100 microsec 25 millisec, and 60 millisec.
37. The method of claim 32 , wherein the pulse voltage delivery is performed using a plurality of pulses.
38. The method of claim 37 , wherein the plurality of pulses ranges from 2 to about 6 pulses.
39. The method of claim 32 , wherein the pulse voltage delivery is performed using a square wave pulse.
40. The method of claim 31 , wherein the tissue is a muscle tissue.
41. The method of claim 31 , wherein the therapeutic gene product is selected from the group consisting of: mRNA templates for translation, ribozymes, antisense RNA, proteins, glycoproteins, lipoproteins, phosphoproteins and polypeptides.
42. The method of claim 41 , wherein the protein is selected from the group consisting of growth hormones, growth factors, cytokines, clotting factors, antigens, and antigenic factors.
43. The method of claim 42 , wherein the clotting factor is a Factor IX.
44. The method of claim 42 , wherein the growth factor is an erythropoietin.
45. The method of claim 42 , wherein the cytokine is an interferon.
46. The method of claim 31 , wherein the poly glutamic acid is a salt of poly-L-glutamic acid and is present in the formulation at a concentration of 1 to 12 mg/ml.
47. The method of claim 46 , wherein the salt of poly-L-glutamic acid is a sodium salt and is present in the formulation at a concentration of about 6 mg/ml.